KR20120091897A - Composition for preventing or treating of fatty liver comprising a taro - Google Patents

Abstract

PURPOSE: A composition containing Calocasia esculenta L. Schott is provided to reduce lipid content in the liver and to prevent and treat fatty liver. CONSTITUTION: A pharmaceutical composition for preventing and treating non-alcoholic fatty liver contains Araceae including Calocasia esculenta L. Schott or konjac. Araceae is a powder type having 60 mesh or less of size. The pharmaceutical composition reduces fat in the liver or intestine. A health functional food for preventing non-alcoholic fatty liver contains Araceae.

Description

Fatty liver preventive and therapeutic composition containing taro {{COMPOSITION FOR PREVENTING OR TREATING OF FATTY LIVER COMPRISING A TARO}

The present invention relates to a fatty liver prophylactic and therapeutic composition comprising taro.

Recent economic growth and improved national income have led to an increase in dietary lipid intake and a decrease in dietary fiber intake which can prevent them, increasing the risk of developing chronic degenerative diseases such as obesity, hyperlipidemia, hypertension and diabetes. There are many ways to treat obesity, including diet, exercise, surgical surgery, behavior modification, and drug therapy. Diet is the most preferred method because it is effective in a short time, and it is known that it is effective to control dietary factors such as total calories and fat intake to lower obesity and blood cholesterol content. As pharmacotherapy, drugs that suppress appetite suppression and digestion and absorption of fat are commercially available depending on the mechanism of causing obesity, but side effects may be a problem. Therefore, in recent years, Garcinia ( Gacinia) as a functional food material showing the efficacy of anti-obesity cambogia ) hydroxycitrate, carnitine, conjugated linoleic acid, and dietary fiber, which are extracted from the skin of fruit, are used as anti-obesity materials. Among them, water-soluble dietary fiber binds with bile acid in the small intestine, which reduces the usefulness of bile, inhibits absorption and increases excretion with feces. have. In addition, it produces a short-chain fatty acid by fermentation of dietary fiber in the large intestine, inhibits liver cholesterol synthesis, and has the effect of replacing saturated fatty acid and cholesterol.

On the other hand, taro is a genus of Araceae and perennial herb, widely cultivated in tropical and temperate regions, with 100 genera and 1,500 varieties distributed worldwide. Taro is low in calories, and the main ingredient is starch. It contains dextrin and sucrose, and has a sweet taste. It is a sticky viscous ingredient and has galactan. Potatoes are relatively high in protein and are rich in essential amino acids, vitamin C and dietary fiber. Taro powder is a powder that is small because it is powdered, and it is known that it is very digestible when food is made and eaten. The high content of dietary fiber is known to alleviate constipation treatment and prevention. As described above, studies on the functionality and food characteristics of taro have been conducted, but studies on the effects of obesity inhibition and lipid lowering through animal experiments using the nutritional and food characteristics of taro powder are still insufficient.

An object of the present invention is to add a taro powder to a high fat diet for 8 weeks after feeding the mouse body weight change, serum and liver lipid content and blood leptin and insulin concentrations, liver metabolism-related enzyme activity and liver tissue Observing the degree of lipid deposition is to provide an anti-obesity composition that inhibits obesity and lowers lipids.

In order to achieve the above object in one embodiment provides a pharmaceutical composition for preventing and treating non-alcoholic fatty liver comprising cheonnamseong. In another embodiment, the cheonnamseong provides a pharmaceutical composition, characterized in that but not limited to taro or konjac. In another embodiment, the cheonnamseong provides a pharmaceutical composition, characterized in that the powder form and the size of the powder is less than 60 mesh (mesh) size. In another embodiment the Cheonnamseong provides a pharmaceutical composition, characterized in that 20 to 50% of the total composition weight. In another embodiment, the pharmaceutical composition provides a pharmaceutical composition, characterized in that to reduce liver fat or visceral fat, wherein the visceral fat is selected from, but not limited to, epididymal fat, peripheral kidney fat, mesenteric fat and epigastric fat. It provides a pharmaceutical composition characterized in that at least one.

In one embodiment, it provides a non-alcoholic fatty liver preventive dietary supplement comprising Cheonnam. In another embodiment, the cheonnamseong provides a health functional food, characterized in that but not limited to taro or konjac. In another embodiment, the Cheonnamseong provides a health functional food, characterized in that the powder form and the size of the powder is less than 60 mesh (mesh) size. In another embodiment, the cheonnamseong provides a dietary supplement, characterized in that 20 to 50% of the total composition weight. In another embodiment, the health functional food provides a health functional food characterized in that it reduces liver fat or visceral fat, the visceral fat is not limited thereto, epididymal fat, peripheral kidney fat, mesenteric fat and posterior cavity fat It provides a health functional food, characterized in that at least one selected from the group consisting of.

In the present invention, "fatty liver" refers to a state in which fat is accumulated in an excess amount of hepatic cells due to a liver fat metabolism disorder. It is responsible for various diseases such as angina pectoris, myocardial infarction, stroke, arteriosclerosis and pancreatitis.

In the present invention, the liver enzymes "AST (aspartate transaminase) and ALT (alanine transaminase)" are distributed in large amounts in the liver and heart, and the activity is markedly increased in concentrations during liver cell damage.

The taro powder composition according to the present invention can improve the fat accumulation in liver tissue by reducing the lipid content present in liver tissue and normalize the activity of liver function indicator enzyme to obtain the effect of preventing and treating fatty liver development.

1 is a graph showing the weight of the liver of rats subjected to high fat and cholesterol diet containing the taro powder for 8 weeks.
Figure 2 is a photograph showing the H & E staining results of liver tissue.
Figure 3 is a graph showing the results of examining the total fat, triglycerides and cholesterol content of the liver.
Figure 4 is a graph showing the liver enzyme levels AST and ALT and glucose levels of rats subjected to high fat and cholesterol diet containing the taro powder for 8 weeks.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example

Example  1. Preparation of Taro Powder

Taro powder is sliced by removing the shell of altoran (altoran produced in Gurye-gun, Jeollanam-do in 2008, stored at 2 ~ 5 ℃ until used for experiment) and dried at 60 ℃ hot air dryer for 30 minutes at atmospheric pressure. After pulverizing with a blender to pass through a sieve of 60 mesh (mesh) to prepare a steamed taro powder having uniform particles. Each taro powder was sealed and stored at 4 ° C. to be used as a sample.

Example  2. Dietary Composition of Taro Powder

Experimental animals were fed four weeks-old male C57 BL / 6J rats from Orient Bio Inc., Seongnam, Korea, and then fed the experimental diet after one week of adaptation. The composition of the experimental diet was shown in Table 1, and the normal diet group was fed AIN-76A diet # 100000 (Dytes Inc., Bethleham, PA, USA), and based on the AIN-76A diet to induce obesity in the experimental group. The high fat diet was prepared by adding lard (31%) and 0.5% cholesterol to induce hypercholesterolemia. In addition, to examine the weight loss and lipid-lowering effects of taro powder, an experimental diet was prepared by adding 20% and 30% taro powder to a high fat diet.

HF ^{1 )} HF-Toran 20% ²⁾ HF-Toran 30% ³⁾ Taro powder 0 20 30 casein 26 22 20 Corn starch 6 0 0 Sucrose 0 0 0 Dextrose 20 12 5 Soybean oil 3.5 2.5 2.0 Donji 31 31 31 Cellulose 6 5 4.5 AIN-mineral mixture 5 5 5 AIN-vitamin mixture 1.3 1.3 1.3 Antioxidant (TBHQ) 0.002 0.002 0.002 Cysteine 0.4 0.4 0.4 Choline Hydrogen Tartrate 0.3 0.3 0.3 cholesterol 0.5 0.5 0.5 gun 100 100 100

¹⁾ HF: high fat and cholesterol diet

²⁾ HF-Toran 20%: High Fat & Cholesterol Diet + Taro Powder 20%

³⁾ HF-Toran 30%: High Fat & Cholesterol Diet + Taro Powder 30%

The experimental group was divided into 4 groups of the normal diet group (Normal), high fat control group (HF), high fat-toro powder 20% group (HF-Taro 20%), high fat-toro powder 30% group (HF-Taro 30%). Divided into eggplant treatment group was raised for 8 weeks. Experimental animals were kept in an environment-controlled breeding room (literally 6:00 pm-6: 00 am, temperature 22 ± 2 ℃), 10 to each group, and 2 to 3 animals were caged. During the breeding, the diet was limited to the average intake once a day, the drinking water was freely ingested, and all experimental diets were kept frozen during the breeding period.

During the breeding period, the body weight of the test animals was measured once a week, and the dietary intake was calculated by measuring the dietary amount and remaining amount at a predetermined time every day. The food efficiency ratio (FER) was calculated as the ratio of weight gain to total diet intake (FER = body weight gain (g) / food intake (g)) for eight weeks.

Example  3. Determination of dietary efficacy of taro powder

The animals were fasted for 12 hours before sacrifice, and collected by orbital blood collection. The collected blood was immediately centrifuged at 3,000 rpm for 15 minutes and serum was used as analytical sample. In addition, organ tissues of the liver, kidney, and testicles, kidney fat, epididymal fat, and brown fat are extracted immediately after blood collection, rinsed in saline solution, and then weighed by removing moisture from the surface, and the liver and epididymal fat are rapidly quenched in liquid nitrogen. Frozen and stored at -70 ° C.

3-1. Liver lipid measurement

Hepatic lipids were repeatedly extracted by adding 10 times the amount of solvent (chloroform: methanol = 2: 1) of liver tissue according to the method of Folch et al. (11), and the solvent was volatilized to obtain lipids. Total lipids, cholesterol, and HDL-cholesterol were analyzed in the same manner as in serum, using extracted lipids as 15 mL of ethanol.

3-2. Blood biochemical analysis

Serum was separated from the collected blood and AST (aspartate transaminase), ALT (alanine transaminase) and glucose (glucose) were measured using the respective commercial assay kit (Bio Clinical System, Korea).

3-3. Liver tissue Lipid deposition  And Calmness  observe

For morphological observation of liver and adipose tissue cells, some of the liver and epididymal tissues were extracted, fixed and dehydrated in 10% formaldehyde solution, and embedded through paraffin permeation. The thin slicer was cut to a thickness of about 4 μm, stained with hematoxylin-eosin (HE), infiltrated with xylene, and sealed, and then observed with an optical microscope.

3-4. Statistical processing

The experimental data were analyzed by ANOVA analysis Ducan's multiple range test using variance analysis using SAS statistical program (SAS Institute Inc., Cary, NC, USA). All items were repeated three times and expressed as mean and standard deviation.

Example  4. Measurement result of dietary efficacy of taro powder

4-1. Improvement of liver hypertrophy

The liver weight of the high fat control group was significantly increased compared to the normal diet group, and the weight of the liver was decreased in the taro powder-added group. It turned pale pink and showed the shape of a typical fatty liver with yellow fats deposited. In particular, in the taro powder 10% and 40% addition group, the weight of the liver was 1.00g or more. Therefore, it can be seen that there is a critical significance in the taro powder 20% addition group. In general, the intake of fat and cholesterol causes abnormal lipid metabolism of liver tissue, which leads to lipid deposition and increases the weight of liver tissue. In this experiment, the high fat and high cholesterol diet of liver tissue of high fat control group The increase is also attributable to this cause. On the other hand, the taro powder added group had less lipid deposition and maintained a similar shape to the normal diet group (FIG. 1).

4-2. Lipid deposition

As a result of H & E staining of liver tissues to confirm the accumulation of lipids (FIG. 2), high fat controls showed hepatic fat accumulation in the hepatocytes, and abundant fatty vesicles appeared in the cytoplasm due to large and small fat droplets in the cytoplasm. It was. In the taro powder added group, hepatic fat deposition was clearly inhibited. It was also observed that the dietary epididymal fat cells were enlarged when fed high fat diet compared to the normal diet group, and the diet of high fat diet with taro powder showed a tendency to significantly reduce the size of the epididymal fat cells.

4-3. Hypolipidemic effect

The result of examining the total fat, triglyceride and cholesterol content of the liver was as shown in FIG. The total amount of fat per unit weight of liver was lowest in the normal diet group (0.04 ± 0.02 g / g) and in the high fat control group (0.13 ± 0.01 g / g). On the other hand, the taro powder added group showed a tendency to decrease significantly compared to the high fat control group, and in the high fat-toran powder 30% group (HF-Toran 30%), it showed a large decrease between 0.07 ± 0.03 g / g. -The taro powder 40% group (HF- taro 30%) did not show a significantly lower value.

Hepatic triglyceride (TG) content was about 3.6-fold higher in the high-fat control group at 725.92 ± 219.11 mg / g compared to the normal diet group at 202.16 ± 76.62 mg / g. Compared with the taro powder added group, the triglyceride content of liver decreased. Especially, the 30% taro powder group showed a significantly lower value of 286.67 ± 19.26 mg / g, but the taro powder 40% group showed a significantly lower value. No value was shown.

The total cholesterol content of the liver also showed a similar tendency, and the concentration of cholesterol was decreased depending on the concentration of taro powder and 31.65 ± 4.52 mg / g in the 30% taro group. HDL cholesterol was 1.30 ± 0.24–2.72 ± 0.50 mg / g. The ratio of HDL cholesterol to total cholesterol was the highest in the normal diet group and there was no significant difference between the high fat control group and the taro powder added group. .

4-4. Liver enzyme level - AST ( GOT ), ALT ( GPT )

The AST enzyme of the high fat control group showed high value of 264.70 ± 60.45 U / L by the high fat diet, but the high fat-toro powder 20% group (HF-Taro 20%) and the high fat-toro powder 30% group ( HF-Taro 30%) had lower AST levels than the normal diet, with 148.73 ± 23.03 U / L and 170.56 ± 69.84 U / L, respectively. In addition, the concentration of ALT enzyme in the high fat control group was 136.38 ± 39.37 U / L, whereas the high fat-toro powder 20% group (HF-Taro 20%) and high fat-toro powder 30% group (HF-Taro 30%) had ALT levels. Were 115.58 ± 37.31 U / L and 113.38 ± 21.88 U / L, respectively, to the normal diet level (FIG. 4). Glucose levels were significantly increased in the high fat control group and showed a tendency to decrease in concentration dependent addition of taro powder.

Formulation example  One: Powder  Produce

300 mg taro powder of Example 1

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation example  2: Preparation of tablets

50 mg taro powder of Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation example  3: Manufacture of capsule

50 mg taro powder of Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation example  4: Preparation of injection

50 mg taro powder of Example 1

Appropriate sterile distilled water for injection

pH adjuster

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation example  5: Liquid  Produce

Taro powder of Example 1 100 mg

10 g of isomerized sugar

5 g of mannitol

Purified water

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

In addition to the above-described active ingredient for administration, it may be prepared by including one or more pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary. And other conventional additives such as bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

The compositions of the present invention can be administered to humans or animals by a variety of routes, including parenteral, intraarterial, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal routes of administration. Dosage varies depending on the weight, age, sex, health status, diet, time of administration, method of administration, rate of excretion, and severity of disease of the patient. The daily dosage of the composition is about 10 ng / kg to 10 mg / kg, preferably about 80 to 400 ng / kg, and more preferably, administered once or several times a day.

Formulation example  6: manufacture of health food

1000 mg of taro powder of Example 1

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

0.13 mg of vitamin B ₁

0.15 mg of vitamin B ₂

0.5 mg of vitamin B ₆

Vitamin B ₁₂ 0.2 g

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

50 μg folic acid

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Formulation example  7: manufacture of health drinks

1000 mg of taro powder of Example 1

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained by sterilization in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.

Although the composition ratio is mixed with a component suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

While the present invention has been described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. You will know. In addition, many modifications may be made to adapt a particular situation and material to the teachings of the invention without departing from the essential scope thereof. Accordingly, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention be construed as including all embodiments falling within the scope of the appended claims.

Claims (14)

Pharmaceutical composition for preventing and treating nonalcoholic fatty liver, including Chunnam Province. The method of claim 1,
The Tiannan Province is a pharmaceutical composition, characterized in that taro or konjac. The method of claim 1,
The cheonnamseong and the pharmaceutical composition, characterized in that the powder form. The method of claim 3, wherein
The powder form is a pharmaceutical composition, characterized in that the size of less than 60 mesh (mesh). The method of claim 1,
The cheonnamseong pharmaceutical composition, characterized in that 20 to 30% of the total composition weight. The method of claim 1,
The pharmaceutical composition is a pharmaceutical composition, characterized in that to reduce the liver fat or visceral fat. The method according to claim 6,
The visceral fat is a pharmaceutical composition, characterized in that at least one selected from epididymal fat, peripheral kidney fat, mesenteric fat and celiac fat. Non-alcoholic fatty liver prevention health functional food, including Cheonnam. The method of claim 8,
Health functional foods, characterized in that the taro or konjac. The method of claim 8,
Health functional food, characterized in that the Cheonnamseong in the form of a powder. The method of claim 10,
The powder form is a health functional food, characterized in that the size of less than 60 mesh (mesh). The method of claim 8,
Health functional foods, characterized in that 20 to 30% of the total composition weight. The method of claim 8,
The health functional food is a health functional food, characterized in that to reduce liver fat or visceral fat. The method of claim 13,
The visceral fat is a health functional food, characterized in that one or more selected from the group consisting of epididymal fat, peripheral kidney fat, mesenteric fat and celiac fat.

Images